Affimed Says FDA Granted Fast Track Designation To Combination Of Its Innate Cell Engager AFM24 With Atezolizumab For EGFR Wild-Type Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Affimed announced that the FDA has granted Fast Track Designation to its combination therapy AFM24 with Atezolizumab for treating advanced and/or metastatic EGFR wild-type non-small cell lung cancer (NSCLC). Data from the AFM24-102 study will be presented at the American Society of Clinical Oncology meeting on June 1, 2024.
May 29, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Affimed's combination therapy AFM24 with Atezolizumab has received FDA Fast Track Designation for treating advanced EGFR wild-type NSCLC. This designation could expedite the development and review process, potentially leading to earlier market entry.
The FDA Fast Track Designation is a significant regulatory milestone that can accelerate the development and review process of AFM24, potentially leading to earlier market entry and revenue generation. This is positive news for Affimed's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100